The Munich-based chemical company, Wacker Chemie AG, acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg.
Founded in 2000, SynCo Bio Partners has some 110 employees and operates two fermentation lines with current capacities of 1,500 and 270 liters. These lines manufacture microbial-derived biopharmaceuticals, not only for clinical testing, but also for the commercial market. There is a further line of single-use fermenters, which provides additional and flexible production capabilities. SynCo’s service offering is rounded out with a fill-and-finish facility, which enables the complete manufacture of pharma-ceuticals from the active agent to the filled product. The facilities meet Good Manufacturing Practice (GMP) quality standards, and they have already been inspected by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and approved for the manufacture of specific pharmaceutical proteins.
Wacker Biotech GmbH is a full-service contract manufacturer of bio-pharmaceutical proteins based on microbial systems. The company’s services range from molecular biology, analytical services and process development through to the GMP-compliant manufacture of clinical test samples and pharmaceutical actives for the commercial market at its German-based Jena and Halle plants, which are GMP compliant, and FDA and EMA certified. Wacker Biotech is a wholly-owned Wacker subsidiary.